Fase-2-obesitasstudie (NEJM, 2023): bij volwassenen met obesitas/overgewicht leidde retatrutide tot gemiddeld ~17,5% gewichtsverlies op 24 weken en tot ~24% op 48 weken (secundaire uitkomst)
doi: 10.1074/jbc.M110.133579 64 MurphyMP
For semaglutide alone, trials relating to cardiovascular disease (SELECT), kidney disease (FLOW) and heart failure (STEP) have announced positive results in the last 12 months
Las reacciones adversas notificadas con ms frecuencia en ambos medicamentos son los trastornos gastrointestinales, las nuseas, la diarrea y los vmitos
This starter dose represents the initial therapeutic step in most tirzepatide treatment protocols
Special considerations for different populations Treatment duration considerations shift based on age, sex, and underlying health conditions